Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Histone deacetylases (HDACs) are crucial epigenetic regulators involved in cancer progression.
• HDAC6, a specific HDAC isoform, plays a significant role in cancer cell proliferation and survival.
• Targeting HDAC6 offers a potential strategy for cancer therapy with potentially fewer side effects than pan-HDAC inhibition.

Purpose of the Study:

• To synthesize and characterize novel hydroxamic acids with a pyridylalanine substructure.
• To evaluate the selectivity of these compounds as inhibitors of human recombinant HDAC6.
• To assess the potential of these HDAC6-selective inhibitors in cancer treatment, including combination therapy.

Main Methods:

• Chemical synthesis of hydroxamic acids incorporating a pyridylalanine moiety.
• In vitro enzymatic assays to determine HDAC6 and HDAC1 inhibition.
• Western blotting analysis of tubulin and histone acetylation in cancer cells.
• Molecular docking studies using an HDAC6 homology model.

Main Results:

• Synthesized compounds selectively inhibited human recombinant HDAC6 with up to 25-fold selectivity over HDAC1.
• Western blot analysis confirmed reduced tubulin and histone acetylation in cancer cells treated with the inhibitors.
• Docking studies revealed specific interactions between the inhibitors' cap group and HDAC6 active site.
• HDAC6-selective compounds exhibited lower cytotoxicity than pan-HDAC inhibitors.

Conclusions:

• Novel hydroxamic acids selectively target HDAC6.
• These compounds demonstrate potential for developing targeted cancer therapies with improved safety profiles.
• Synergistic effects with bortezomib suggest a promising avenue for combination anticancer treatment.